BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2023 6:38:44 AM | Browse: 371 | Download: 1162
 |
Received |
|
2022-09-19 16:40 |
|
Peer-Review Started |
|
2022-09-19 16:42 |
|
First Decision by Editorial Office Director |
|
2022-12-13 02:47 |
|
Return for Revision |
|
2022-12-13 02:47 |
|
Revised |
|
2022-12-22 11:43 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-01-09 03:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-01-09 09:15 |
|
Articles in Press |
|
2023-01-09 09:15 |
|
Edit the Manuscript by Language Editor |
|
2023-01-06 04:56 |
|
Typeset the Manuscript |
|
2023-01-10 10:03 |
|
Publish the Manuscript Online |
|
2023-02-06 06:38 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Pneumocystis jirovecii diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qing-Wei Cheng, Hong-Li Shen, Zhi-Hui Dong, Qian-Qian Zhang, Ya-Fen Wang, Jin Yan, Yu-Sheng Wang and Ning-Gang Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ning-Gang Zhang, MD, Associate Chief Physician, Department of Gastrointestinal Oncology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigong Xincun Street, Xinhualing District, Taiyuan 030013, Shanxi Province, China. zng1120@163.com |
| Key Words |
Renal cell carcinoma; Everolimus; Pneumocystis jirovecii pneumonia; Next-generation sequencing; Bronchoscopic alveolar lavage fluid; Case report |
| Core Tip |
The application of molecular targeted agents and immune checkpoint inhibitors have greatly improved the prognosis of advanced renal cell carcinoma (RCC). We report a patient with advanced RCC treated with multiple lines of molecular targeted agents, who developed a Pneumocystis jirovecii pneumonia after treatment with everolimus in combination with lenvatinib. The pathogenic organism was identified by next-generation sequencing (NGS) of bronchoscopic alveolar lavage fluid (BALF) and successfully treated with trimethoprim-sulfamethoxazole. Evaluating BALF with NGS technology might be used to detect pathogens and determine the correct treatment plan for patients with rare infections caused by the use of molecular targeted agents. |
| Publish Date |
2023-02-06 06:38 |
| Citation |
Cheng QW, Shen HL, Dong ZH, Zhang QQ, Wang YF, Yan J, Wang YS, Zhang NG. Pneumocystis jirovecii diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature. World J Clin Cases 2023; 11(4): 866-873 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i4/866.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i4.866 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
